76 related articles for article (PubMed ID: 9410098)
1. [Frequency and characteristics of patients treated with zidovudine and absence of progression of HIV infection].
Soriano V; Heredia A; Mas A; Vallejo A; Garćia-Lerma G; Bravo R; Gómez-Cano M; Villalba N; Moreno V; Laguna F; Valencia E; Martínez P; González-Lahoz J
An Med Interna; 1997 Jun; 14(6):282-5. PubMed ID: 9410098
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
[TBL] [Abstract][Full Text] [Related]
3. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
4. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
5. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
6. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
van't Wout AB; Ran LJ; de Jong MD; Bakker M; van Leeuwen R; Notermans DW; Loeliger AE; de Wolf F; Danner SA; Reiss P; Boucher CA; Lange JM; Schuitemaker H
J Clin Invest; 1997 Nov; 100(9):2325-32. PubMed ID: 9410911
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. HIV infection and zidovudine use in childbearing women.
Sia J; Paul S; Martin RM; Cross H
Pediatrics; 2004 Dec; 114(6):e707-12. PubMed ID: 15545619
[TBL] [Abstract][Full Text] [Related]
10. Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods.
Kuhn L; Abrams EJ; Weedon J; Lambert G; Schoenbaum EE; Nesheim SR; Palumbo P; Vink PE; Bulterys M
J Infect Dis; 2000 Jul; 182(1):104-11. PubMed ID: 10882587
[TBL] [Abstract][Full Text] [Related]
11. Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. The Italian register for HIV Infection in Children.
AIDS; 1999 May; 13(8):927-33. PubMed ID: 10371173
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection--the Quattro Trial. Quattro Steering Committee.
AIDS; 1999 Nov; 13(16):2209-17. PubMed ID: 10563706
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
14. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of zidovudine in monotherapy in patients with HIV infection].
Martín Fernández J; Rubio García R; Pulido Ortega F; Crespo Garzón AE; Esteban Fernández FJ; Costa Pérez-Herrero JR; del Palacio Pérez-Medel A
An Med Interna; 1998 Mar; 15(3):125-31. PubMed ID: 9567421
[TBL] [Abstract][Full Text] [Related]
16. [Rapid and slow progression of the infection by the type 1 human immunodeficiency virus in a population of seropositive subjects in Madrid].
Soriano V; Martín R; del Romero J; Castilla J; Bru F; Bravo R; Gutiérrez M; Martínez P; Valencia E; García S; Mas A; Moreno V; Laguna F; Rodríguez C; Sabín ML; González-Lahoz J
Med Clin (Barc); 1996 Dec; 107(20):761-6. PubMed ID: 9019602
[TBL] [Abstract][Full Text] [Related]
17. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
18. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
[TBL] [Abstract][Full Text] [Related]
19. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
20. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F;
Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
